1. Home
  2. OSRH vs SNGX Comparison

OSRH vs SNGX Comparison

Compare OSRH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc. Common Stock

OSRH

OSR Holdings Inc. Common Stock

HOLD

Current Price

$0.69

Market Cap

12.5M

Sector

N/A

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.65

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
SNGX
Founded
N/A
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
13.8M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
OSRH
SNGX
Price
$0.69
$1.65
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
11.7M
244.8K
Earning Date
11-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$1.09
52 Week High
$12.54
$6.23

Technical Indicators

Market Signals
Indicator
OSRH
SNGX
Relative Strength Index (RSI) 54.57 59.19
Support Level $0.67 $1.25
Resistance Level $0.76 $1.60
Average True Range (ATR) 0.10 0.12
MACD 0.01 0.04
Stochastic Oscillator 54.93 95.12

Price Performance

Historical Comparison
OSRH
SNGX

About OSRH OSR Holdings Inc. Common Stock

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: